Tempus Acquires Highline Sciences
February 8, 2022
Tempus, the Chicago-based AI-driven precision medicine company, has acquired Highline Sciences, a San Francisco-based full-service clinical CRO focused on oncology. The acquisition will allow Tempus to vertically integrate additional clinical trial services and expand its capabilities to support and grow clinical research offerings for oncology therapeutics.
- Buyers
- Tempus
- Targets
- Highline Sciences
- Industry
- Healthcare Services
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Tempus Acquires Deep 6 AI
March 11, 2025
Healthcare Services
Tempus AI, Inc. (NASDAQ: TEM) has acquired Deep 6 AI, an AI-powered precision research platform that matches patients to clinical trials by mining structured and unstructured EMR data. The acquisition expands Tempus' provider network (Deep 6 is integrated with 750+ provider sites covering more than 30 million patients) and enhances Tempus' clinical-trial matching and real-world evidence capabilities to accelerate recruitment and RWE generation.
-
NeoGenomics Acquires Pathline
April 7, 2025
Healthcare Services
NeoGenomics, Inc. (NASDAQ: NEO) has completed its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified pathology laboratory headquartered in Ramsey, New Jersey. The deal strengthens NeoGenomics' commercial presence in the Northeast United States and expands its molecular and hematology-oncology testing capabilities and access to its oncology test menu.
-
Tempus AI Acquires Paige for $81.25 Million
August 25, 2025
Healthcare Services
Tempus AI, Inc. (NASDAQ: TEM) is acquiring digital pathology company Paige for $81.25 million, primarily paid in Tempus common stock, and will assume Paige's remaining Microsoft Azure commitments. The deal expands Tempus's pathology dataset, technical team, and generative AI capabilities to accelerate development of large oncology foundation models and strengthen its precision medicine platform.
-
Taconic Biosciences Acquires TransCure bioServices
January 20, 2026
Biotechnology
Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.
-
Altasciences Acquires Sinclair Research
January 4, 2022
Healthcare Services
Altasciences completed the acquisition of Sinclair Research, a Midwest-based preclinical CRO, expanding its U.S. preclinical footprint and adding capacity and toxicology expertise. The deal brings Sinclair’s over-80-animal-room capabilities into Altasciences’ integrated CRO/CDMO platform to better support biopharmaceutical, animal health, and medical device development programs.
-
H.I.G. Capital Acquires Celerion
November 3, 2022
Healthcare Services
H.I.G. Capital (through an affiliate) completed the acquisition of Celerion Holdings, Inc., a global clinical research organization headquartered in Lincoln, Nebraska. Celerion provides end-to-end early-stage clinical trial and bioanalytical services to pharmaceutical and biotechnology clients; H.I.G. said the investment expands its pharma services platform and supports Celerion's growth plans.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.